Jump to content

Axomadol

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Mfernflower (talk | contribs) at 03:31, 4 October 2023. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Axomadol
Clinical data
ATC code
  • None
Legal status
Legal status
  • US: ?
Identifiers
  • (1R,3R,6R)-6-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-1,3-cyclohexanediol
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC16H25NO3
Molar mass279.380 g·mol−1
3D model (JSmol)
  • O[C@]2(c1cc(OC)ccc1)C[C@H](O)CC[C@@H]2CN(C)C
  • InChI=1S/C16H25NO3/c1-17(2)11-13-7-8-14(18)10-16(13,19)12-5-4-6-15(9-12)20-3/h4-6,9,13-14,18-19H,7-8,10-11H2,1-3H3/t13-,14-,16+/m1/s1
  • Key:LQJLLAOISDVBJM-FMKPAKJESA-N

Axomadol (INN, USAN) (code name EN3324) is a synthetic, centrally-acting opioid analgesic related to tramadol which was under investigation by Endo Pharmaceuticals in collaboration with Grünenthal GmbH for the treatment of chronic, moderate to severe lower back pain and arthrosis.[1][2] Development was halted after phase II clinical trials as it did not meet the pre-determined clinical endpoints.[3]

See also

References

  1. ^ Ford C (2011-06-30). "Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain" (Press release). Endo Pharmaceuticals. Retrieved 2012-05-11.
  2. ^ US Abandoned 20100331424, Schiene K, Bloms-Funke P, Bothmer J, Lefeber C, "Use of Axomadol for Treatment of Arthrosis Pain", published 2010-12-30, assigned to Grünenthal GmbH 
  3. ^ Ford C (2011-08-17). "Endo Pharmaceuticals Announces Termination of Collaboration with Grunenthal for the Development of Axomadol" (Press release). Endo Pharmaceuticals. Retrieved 2012-05-11.



Stub icon

This analgesic-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Axomadol&oldid=1178509233"